Investors
Overview

Investors Overview

Company Profile

Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's lead candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD).

Featured Video

Press Releases
Read more
Recent/Upcoming Events
May 29, 2026 at 8:30 AM CEST
EASL Congress 2026 - Poster Presentations

Session: MASLD: Therapy (TOP-176)

Title: Concurrent Responses in Multiple Non-Invasive Tests for Hepatic Inflammation and Fibrosis Following Pemvidutide Treatment: 24-Week Responder Analyses from the Phase 2b IMPACT Trial

Speaker: Dr. Scot Roberts, Chief Scientific Officer, Altimmune

Session: MASLD: Therapy (FRI-201)

Title: Effect of Pemvidutide on Cardiovascular Risk Factors in Patients with MASH: 48-Week Results from the Phase 2b IMPACT Trial

Speaker: Dr. Shaheen Tomah, Director, Clinical Development, Altimmune

May 28, 2026 at 5:00 PM CEST
EASL Congress 2026 - Oral Presentation

Session: MASLD: Clinical and Therapeutic Aspects I (OS-016)

Title: Week 48 Top-Line Results from the Phase 2b, Multicenter, Randomized, Placebo-Controlled IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis

Speaker: Dr. Mazen Noureddin, Professor of Medicine, Houston Methodist Hospital; Chief Scientific Officer and Co-Chairman, Summit Clinical Research

May 27, 2026 at 8:30 AM CEST
EASL Congress 2026 - Late-Breaking Poster

Session: Late Breaker Posters (LBP-036)

Abstract Title: Pemvidutide Treatment Led to Fibrosis Regression After 24 Weeks in Patients with MASH: Quantitative Digital Pathology Analysis from the Phase 2b IMPACT Trial

Speaker: Dr. Shaheen Tomah, Director, Clinical Development, Altimmune

View all

Corporate Governance

Corporate Presentation
 

Investor Contact

Email: ir@altimmune.com

 

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe